Subtopic Deep Dive
SLCO2A1 Mutations in Osteoarthropathy
Research Guide
What is SLCO2A1 Mutations in Osteoarthropathy?
SLCO2A1 mutations cause loss-of-function in the prostaglandin transporter, leading to prostaglandin E2 accumulation that drives primary hypertrophic osteoarthropathy (PHO) and chronic enteropathy associated with SLCO2A1 (CEAS).
Loss-of-function variants in SLCO2A1 impair prostaglandin clearance, resulting in clinical features like digital clubbing, pachydermia, periostosis, and small intestinal ulcers. Over 10 key papers since 2012, including Umeno et al. (2015, 141 citations) identifying SLCO2A1 in hereditary enteropathy and Diggle et al. (2012, 95 citations) linking mutations to PHO with myelofibrosis, define this subtopic. Recent works distinguish CEAS from Crohn's disease (Umeno et al., 2018, 73 citations).
Why It Matters
SLCO2A1 mutations enable genetic screening for PHO and CEAS, distinguishing these from inflammatory bowel diseases like Crohn's, as shown by immunohistochemical SLCO2A1 staining (Yanai et al., 2018). Elevated PGE2 levels from transporter defects inform targeted prostaglandin pathway inhibitors, improving management of pachydermia and ulcers (Lu et al., 2023). Korean cohort studies confirm recessive inheritance patterns, aiding precise diagnosis in Asian populations (Lee et al., 2016).
Key Research Challenges
Distinguishing CEAS from Crohn's
CEAS mimics Crohn's with small intestinal ulcers but lacks granulomas and responds differently to therapies. Umeno et al. (2018) highlight distinct clinical features and recommend SLCO2A1 genetic testing. Yanai et al. (2018) propose immunohistochemical staining for definitive separation.
Genotype-Phenotype Correlation
Varied SLCO2A1 mutations produce overlapping PHO and enteropathy phenotypes, complicating predictions. Diggle et al. (2012) link mutations to myelofibrosis in PHO, while Busch et al. (2012) associate them with digital clubbing. Lu et al. (2023) review incomplete penetrance in dominant vs. recessive cases.
Therapeutic Targeting of PGE2
Elevated PGE2 drives symptoms, but specific inhibitors are lacking beyond NSAIDs. Giancane et al. (2015) discuss symptomatic management, while Tanese et al. (2015) characterize pachydermia pathology. No trials target SLCO2A1 restoration directly.
Essential Papers
A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter
Junji Umeno, Tadakazu Hisamatsu, Motohiro Esaki et al. · 2015 · PLoS Genetics · 141 citations
Previously, we proposed a rare autosomal recessive inherited enteropathy characterized by persistent blood and protein loss from the small intestine as chronic nonspecific multiple ulcers of the sm...
Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
Christine P. Diggle, David Parry, Clare V. Logan et al. · 2012 · Human Mutation · 95 citations
Pachydermoperiostosis, or primary hypertrophic osteoarthropathy (PHO), is an inherited multisystem disorder, whose features closely mimic the reactive osteoarthropathy that commonly accompanies neo...
Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease
Junji Umeno, Motohiro Esaki, Atsushi Hirano et al. · 2018 · Journal of Gastroenterology · 73 citations
The clinical features of CEAS are distinct from those of Crohn's disease. Genetic analysis of the SLCO2A1 gene is therefore recommended in patients clinically suspected of having CEAS.
Mutations in the Prostaglandin Transporter SLCO2A1 Cause Primary Hypertrophic Osteoarthropathy with Digital Clubbing
Jutta Busch, Valeska Frank, Nadine Bachmann et al. · 2012 · Journal of Investigative Dermatology · 52 citations
Chronic Enteropathy Associated With SLCO2A1 Gene [CEAS]—Characterisation of an Enteric Disorder to be Considered in the Differential Diagnosis of Crohn’s Disease
Naoki Hosoe, Naoki Ohmiya, Fumihito Hirai et al. · 2017 · Journal of Crohn s and Colitis · 49 citations
Small intestinal ulcers include mucosal damage caused by drugs, particularly nonsteroidal anti-inflammatory drugs [NSAIDs], infectious diseases, and idiopathic inflammatory bowel disease. Previousl...
Pathological characterization of pachydermia in pachydermoperiostosis
Keiji Tanese, Hironori Niizeki, Atsuhito Seki et al. · 2015 · The Journal of Dermatology · 38 citations
Abstract Pachydermoperiostosis is a rare hereditary disease, which presents with the cutaneous manifestations of pachydermia and cutis verticis gyrata. Histological findings in pachydermia frequent...
Primary hypertrophic osteoarthropathy: genetics, clinical features and management
Qi Lu, Yang Xu, Zeng Zhang et al. · 2023 · Frontiers in Endocrinology · 37 citations
Primary hypertrophic osteoarthropathy (PHO) is a genetic disorder mainly characterized by clubbing fingers, pachydermia and periostosis. Mutations in the HPGD or SLCO2A1 gene lead to impaired prost...
Reading Guide
Foundational Papers
Start with Diggle et al. (2012, 95 citations) for PHO-myelofibrosis link and Busch et al. (2012, 52 citations) for clubbing mutations, as they establish SLCO2A1 causality via sequencing.
Recent Advances
Lu et al. (2023, 37 citations) for genetics/management update; Umeno et al. (2018, 73 citations) for CEAS clinical features; Yanai et al. (2018, 28 citations) for diagnostic staining.
Core Methods
Whole-exome sequencing (Umeno 2015); immunohistochemistry (Yanai 2018); PGE2 level assays (Busch 2012); histological pachydermia analysis (Tanese 2015).
How PapersFlow Helps You Research SLCO2A1 Mutations in Osteoarthropathy
Discover & Search
Research Agent uses searchPapers('SLCO2A1 mutations hypertrophic osteoarthropathy') to retrieve Umeno et al. (2015, 141 citations), then citationGraph to map 95-citation Diggle et al. (2012) connections, and findSimilarPapers for CEAS vs. Crohn's distinctions like Yanai et al. (2018). exaSearch uncovers Korean PDP cohorts (Lee et al., 2016).
Analyze & Verify
Analysis Agent applies readPaperContent on Diggle et al. (2012) to extract mutation details, verifyResponse with CoVe against Lu et al. (2023) for PGE2 claims, and runPythonAnalysis to plot genotype-phenotype correlations from extracted variant data using pandas. GRADE grading scores evidence as high for SLCO2A1 causality in PHO.
Synthesize & Write
Synthesis Agent detects gaps in therapeutic trials via contradiction flagging between symptomatic reports (Giancane et al., 2015) and PGE2 elevation (Busch et al., 2012), while Writing Agent uses latexEditText for case reports, latexSyncCitations for 10+ papers, and latexCompile for reviews. exportMermaid visualizes mutation-PGE2-periostosis pathways.
Use Cases
"Extract SLCO2A1 variants from PHO papers and plot mutation frequencies"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Diggle 2012, Busch 2012) → runPythonAnalysis (pandas frequency plot, matplotlib export) → researcher gets CSV of variants with prevalence stats.
"Write LaTeX review distinguishing CEAS from Crohn's with SLCO2A1 citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro), latexSyncCitations (Umeno 2018, Yanai 2018), latexCompile → researcher gets PDF manuscript with formatted figures.
"Find GitHub repos analyzing SLCO2A1 sequences in osteoarthropathy"
Research Agent → paperExtractUrls (Lee 2016) → paperFindGithubRepo → githubRepoInspect → researcher gets code for variant calling and prostaglandin models.
Automated Workflows
Deep Research workflow scans 50+ SLCO2A1 papers via searchPapers → citationGraph → structured report on mutation spectra (e.g., Diggle 2012 cluster). DeepScan's 7-step chain verifies CEAS diagnostics: readPaperContent (Umeno 2018) → CoVe → GRADE. Theorizer generates PGE2 inhibition hypotheses from Lu et al. (2023) and Giancane et al. (2015).
Frequently Asked Questions
What defines SLCO2A1 mutations in osteoarthropathy?
SLCO2A1 loss-of-function variants block prostaglandin transport, causing PGE2 accumulation in PHO (clubbing, pachydermia, periostosis) and CEAS (small intestinal ulcers), as in Umeno et al. (2015) and Diggle et al. (2012).
What methods confirm SLCO2A1-related conditions?
Whole-exome sequencing identifies mutations (Umeno et al., 2015); immunohistochemical SLCO2A1 staining distinguishes CEAS from Crohn's (Yanai et al., 2018). Genetic analysis is recommended for suspected cases (Umeno et al., 2018).
What are key papers on SLCO2A1 mutations?
Umeno et al. (2015, PLoS Genetics, 141 citations) discovered SLCO2A1 in enteropathy; Diggle et al. (2012, 95 citations) linked to PHO/myelofibrosis; Busch et al. (2012, 52 citations) to digital clubbing.
What open problems exist?
Therapeutics targeting PGE2 beyond NSAIDs; full genotype-phenotype maps across ethnicities; distinction from secondary osteoarthropathy, as noted in Lu et al. (2023) and Giancane et al. (2015).
Research Hypertrophic osteoarthropathy and related conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching SLCO2A1 Mutations in Osteoarthropathy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers